Notably, the mortality rate after brain radiotherapy was significantly higher in tumors carrying somatic MET mutations compared with euploid wild-type MET lesions (p < 0.008) (Figure 1b); (ii) RON is mutated at a high frequency in brain metastases from lung cancers (9.5%) compared with an unselected cancer population (1%, data from COSMIC database, website at https://cancer.sanger.ac.uk/cosmic). This evidence concerns the gene MST1R and lung carcinoma.